引用次数
引用: 97,128
H-指数: 136
I10-指数 : 357
出版物: 680
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
M. Catherine Pietanza , Shirish M. Gadgeel , Afshin Dowlati , Thomas J. Lynch
Journal of Thoracic Oncology 7 ( 5) 856 -865
35
2012
Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
Sandra P. D’Angelo , Yelena Y. Janjigian , Nicholas Ahye , Gregory J. Riely
Journal of Thoracic Oncology 7 ( 12) 1815 -1822
126
2012
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
Helena A. Yu , Camelia S. Sima , James Huang , Stephen B. Solomon
Journal of Thoracic Oncology 8 ( 3) 346 -351
327
2013
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
Anna M. Varghese , Camelia S. Sima , Jamie E. Chaft , Melissa L. Johnson
Journal of Thoracic Oncology 8 ( 1) 123 -125
24
2013
Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers
Jamie E. Chaft , Valerie Rusch , Michelle S. Ginsberg , Paul K. Paik
Journal of Thoracic Oncology 8 ( 8) 1084 -1090
124
2013
Unsuspected Collision of Synchronous Lung Adenocarcinomas: A Potential Cause of Aberrant Driver Mutation Profiles
Natasha Rekhtman , Laetitia Borsu , Boris Reva , Maria Arcila
Journal of Thoracic Oncology 9 ( 1)
8
2014
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Helena A. Yu , Shaozhou K. Tian , Alexander E. Drilon , Laetitia Borsu
JAMA Oncology 1 ( 7) 982 -984
226
2015
EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression
Allan R. Li , Dhananjay Chitale , Gregory J. Riely , William Pao
The Journal of Molecular Diagnostics 10 ( 3) 242 -248
234
2008
KRAS Mutations: An Old Oncogene Becomes a New Predictive Biomarker
Gregory J. Riely , Marc Ladanyi
The Journal of Molecular Diagnostics 10 ( 6) 493 -495
43
2008
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Gregory J. Riely , William Pao , DuyKhanh Pham , Allan R. Li
Clinical Cancer Research 12 ( 3) 839 -844
837
2006
Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
Gregory J. Riely , Katerina A. Politi , Vincent A. Miller , William Pao
Clinical Cancer Research 12 ( 24) 7232 -7241
332
2006
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Marissa N. Balak , Yixuan Gong , Gregory J. Riely , Romel Somwar
Clinical Cancer Research 12 ( 21) 6494 -6501
937
2006
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M. Samstein , Chung-Han Lee , Alexander N. Shoushtari , Matthew D. Hellmann
Nature Genetics 51 ( 2) 202 -206
2,290
2019
Placental Protein 14 Functions as a Direct T-Cell Inhibitor
Jacob Rachmilewitz , Gregory J. Riely , Mark L. Tykocinski
Cellular Immunology 191 ( 1) 26 -33
82
1999
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu , Maria E. Arcila , Natasha Rekhtman , Camelia S. Sima
Clinical Cancer Research 19 ( 8) 2240 -2247
1,407
2013
Characteristics of Lung Cancers Harboring NRAS Mutations
Kadoaki Ohashi , Lecia V. Sequist , Maria E. Arcila , Christine M. Lovly
Clinical Cancer Research 19 ( 9) 2584 -2591
156
2013
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Justin F. Gainor , Anna M. Varghese , Sai-Hong Ignatius Ou , Sheheryar Kabraji
Clinical Cancer Research 19 ( 15) 4273 -4281
347
2013
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Yelena Y. Janjigian , Maria E. Arcila , Camelia S. Sima , Samantha L. Kass
Clinical Cancer Research 17 ( 19) 6322 -6328
43
2011
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
Jamie E. Chaft , Geoffrey R. Oxnard , Camelia S. Sima , Mark G. Kris
Clinical Cancer Research 17 ( 19) 6298 -6303
438
2011
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
M. Catherine Pietanza , Kyuichi Kadota , Kety Huberman , Camelia S. Sima
Clinical Cancer Research 18 ( 4) 1138 -1145
104
2012